IKT
Inhibikase Therapeutics Inc
2.00$
+3.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 17 | Q4 17 | Q1 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +222.3% | -13.3% | +94.6% | -56.1% | -71.8% | -25.5% | +93.1% | +12.7% | -18.9% | -82.8% | +352.3% | +725.7% | -3.1% | -75.9% | -99.4% | +2,267.8% | -85.8% | +11.3% | +1,593.0% | -47.7% | +80.4% | -31.6% | -100.0% | -100.0% | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | +210.4% | -26.6% | +129.8% | +15.7% | -69.5% | -46.2% | +5.1% | +5.7% | -7.0% | -54.2% | +88.2% | +971.6% | -2.0% | +32.4% | +7.5% | -11.0% | -1.2% | -99.9% | +199.9% | +0.0% | +3,056.9% | -95.9% | +0.0% | +0.0% | +0.0% | 0.0% | 0.0% | +92.7% | +90.9% | -1.9% | +55.4% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +2,010.5% | -49.8% | -171.9% | – | -109.0% | – | – | – | – | – | – | – | – | – | – | – | |
| – | +133.6% | -2.5% | +149.6% | +6.5% | -69.5% | -46.2% | +5.1% | +5.7% | -7.0% | -54.2% | +88.2% | +971.6% | -2.0% | +32.4% | +7.5% | -11.0% | -1.2% | 0.0% | +2.4% | -6.5% | +58.9% | -28.9% | -6.9% | -8.4% | +11.8% | +36.2% | +71.5% | +46.3% | -49.9% | +45.1% | -16.9% | +70.5% | +23.6% | – | |
| – | – | – | – | – | +164.5% | – | – | +33.7% | -29.8% | +56.8% | +351.6% | +0.0% | -38.7% | +2.2% | +0.5% | +1.0% | -0.3% | -7.5% | -12.6% | +43.2% | -7.4% | -9.0% | -13.7% | +45.0% | -2.8% | -17.1% | +250.2% | -8.5% | +12.8% | -5.2% | +20.7% | +8.9% | +3.8% | – | |
| – | +337.9% | -70.5% | +1,089.2% | -33.5% | +35.0% | -48.5% | -67.2% | +33.7% | -29.8% | +56.8% | +97.0% | +39.9% | +0.5% | +2.2% | +0.5% | +1.0% | -0.3% | +171.5% | -4.1% | +10.1% | +29.0% | -21.4% | -9.2% | +8.6% | +5.8% | +15.4% | +121.7% | +13.0% | -25.8% | +17.9% | +7.9% | +32.2% | +15.6% | – | |
| – | – | -309.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -34.8% | +52.8% | +39.4% | -0.8% | -4.2% | +7.0% | -13.3% | +3.6% | +65.2% | -33.8% | -98.0% | +0.6% | -96.8% | -100.0% | – | +201.7% | +324.1% | +79.0% | -86.8% | +1,083.2% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -380.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +24.4% | -100.0% | +100.0% | -50.0% | – | – | – | – | – | – | – | – | – | |
| – | – | -380.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.